TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024

Transcode Therapeutics, Inc.

Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.
Post-split shares outstanding approx 696,233 (includes recent private placement shares).
Split intended to regain compliance with Nasdaq minimum $1.00 bid price; no assurance of continued listing.
Fractional shares rounded up; no change in authorized shares; symbol RNAZ remains.
Vstock Transfer acting as exchange agent; stockholders need not take action.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Transcode Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-33 reverse stock split of common stock (effective 2024-12-04).

Change: charter amendment
Effective: 2024-12-04

Exact text from the filing

On November 26, 2024, TransCode Therapeutics, Inc., (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation to effect a 1-for-33 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), as of 12:01 a.m. Eastern Time on December 4, 2024 (the “Effective Time”).

View on SEC.gov

Browse all governance changes →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-124097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.